机器人辅助根治性前列腺切除术对骨寡转移前列腺癌患者的获益研究
该回顾性研究纳入2005至2015年在本院接受治疗的79例骨寡转移前列腺癌患者,其中38例接受机器人辅助根治性前列腺切除术(RARP),41例接受单纯雄激素剥夺治疗(ADT)。RARP组中位无进展生存期(PFS)为75个月,ADT组为28个月(P=0.008);中位癌症特异性生存期(CSS)RARP组未达到,ADT组为40个月(P=0.002)。多因素分析显示RARP是PFS和CSS的显著预测因素。
要点
- RARP组中位PFS 75个月 vs ADT组28个月(P=0.008)。
- RARP组中位CSS未达到 vs ADT组40个月(P=0.002)。
- 多因素分析RARP预测PFS的HR 0.388(P=0.003),预测CSS的HR 0.264(P=0.004)。
核心结论
- 在骨寡转移前列腺癌中,RARP是安全可行的手术,可改善PFS和CSS。
- 数据提示RARP可有效预防前列腺癌引起的尿路并发症。
- 研究结果来自专家外科医生和高选择患者,不能外推至所有骨寡转移前列腺癌患者;需大型前瞻性多中心研究证实。
研究设计与样本
- 回顾性研究,纳入2005至2015年在本院接受RARP或ADT治疗的79例骨寡转移前列腺癌患者。
- 38例接受RARP,41例接受单纯ADT无局部治疗。
- 骨寡转移定义为术前骨扫描检测到五个或以下热区。
主要发现
- RARP组术后并发症与既往根治性前列腺切除术报道相似,尿路并发症少于ADT组。
- RARP组中位PFS 75个月 vs ADT组28个月(P=0.008)。
- RARP组中位CSS未达到 vs ADT组40个月(P=0.002)。
- 多因素分析显示RARP是PFS的显著预测因素(HR 0.388,P=0.003)。
- 多因素分析显示RARP是CSS的显著预测因素(HR 0.264,P=0.004)。
关键数值与推荐
- 骨寡转移定义:术前骨扫描检测到五个或以下热区。
- RARP组中位PFS 75个月 vs ADT组28个月(P=0.008)。
- RARP组中位CSS未达到 vs ADT组40个月(P=0.002)。
- RARP预测PFS的HR 0.388(P=0.003);预测CSS的HR 0.264(P=0.004)。
临床怎么用
- 原文结论认为RARP在骨寡转移前列腺癌中是安全可行的手术,可改善PFS和CSS。
- 原文指出研究结果来自专家外科医生和高选择患者,不能外推至所有骨寡转移前列腺癌患者。
- 原文建议需大型前瞻性多中心研究证实上述发现。
局限性
- 研究为回顾性研究。
- 研究结果来自专家外科医生和高选择患者,不能外推至所有骨寡转移前列腺癌患者。
- 需大型前瞻性多中心研究证实 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the peri-operative and oncological outcomes of robot-assisted radical prostatectomy (RARP) in patients with oligometastatic prostate cancer (PCa). PATIENTS AND METHODS: We retrospectively reviewed the records of 79 patients with oligometastatic PCa treated with RARP or androgen deprivation therapy (ADT) between 2005 and 2015 at our institution. Of these 79 patients, 38 were treated with RARP and 41 were treated with ADT without local therapy. Oligometastatic disease was defined as the presence of five or fewer hot spots detected by preoperative bone scan. We evaluated peri-operative outcomes, progression-free survival (PFS), and cancer-specific survival (CSS). We analysed data using Kaplan-Meier methods, with log-rank tests and multivariate Cox regression models. RESULTS: Patients treated with RARP experienced similar postoperative complications to those previously reported in RP-treated patients, and fewer urinary complications than ADT-treated patients. PFS and CSS were longer in RARP-treated compared with ADT-treated patients (median PFS: 75 vs 28 months, P = 0.008; median CSS: not reached vs 40 months, P = 0.002). Multivariate analysis further identified RARP as a significant predictor of PFS and CSS (PFS: hazard ratio [HR] 0.388, P = 0.003; CSS: HR 0.264, P = 0.004). CONCLUSIONS: We showed that RARP in the setting of oligometastatic PCa is a safe and feasible procedure which improves oncological outcomes in terms of PFS and CSS. In addition, our data suggest that RARP effectively prevents urinary tract complications from PCa. The study highlights results from expert surgeons and highly selected patients that cannot be extrapolated to all patients with oligometastatic PCa; to confirm our findings, large, prospective, multicentre studies are required.
引用
- Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2017. PMID: 28834084. doi:10.1111/bju.13992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。